3 Global Pharma Company, Generic Formulations Maker and Advanced Pharma Intermediates Maker Stocks With a Strong Future Roadmap: Lupin, Alembic Pharmaceuticals and Acutaas Chemicals

Global generic, formulation and chemistry stocks offer a focused view of a sector where demand keeps widening. Lupin, Alembic Pharmaceuticals and Acutaas Chemicals cover a global pharma company, a generic formulations maker and an advanced pharma intermediates maker.

This list covers three global generic, formulation and chemistry stocks with complete current figures: Lupin, Alembic Pharmaceuticals and Acutaas Chemicals. Every figure comes from the latest reported financials and the 30 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Global Generic, Formulation and Chemistry Stocks?

Global generic, formulation and chemistry stocks are listed companies that sell branded generics and specialty medicines in India and overseas, supply generic formulations to the United States and other markets, and make advanced intermediates for pharma and battery uses. Their earnings depend on approvals, export orders and product mix.

Global Generic, Formulation and Chemistry Stocks at a Glance

On valuation, Lupin and Alembic Pharmaceuticals trade at a P/E below the industry P/E, while Acutaas Chemicals trades above it, which reflects the growth the market already expects. Readers comparing global generic, formulation and chemistry stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Global Generic, Formulation and Chemistry Stocks Have a Strong Roadmap in India?

Global generic, formulation and chemistry stocks have a strong roadmap in India because steady demand for generics, new product approvals and wider use of advanced chemistry keep widening the market for these pharma and chemical companies.

• Generic demand. Regulated markets buy more generics.
• Approvals. New launches add to the product basket.
• Advanced chemistry. Intermediates serve pharma and batteries.

Why Lupin Features Among These Global Generic, Formulation and Chemistry Stocks

Among the global generic, formulation and chemistry stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%.

In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Why Alembic Pharmaceuticals Features Among These Global Generic, Formulation and Chemistry Stocks

Among the pharma export shares on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%.

Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.

Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.

Why Acutaas Chemicals Features Among These Global Generic, Formulation and Chemistry Stocks

Among the three companies on this list, Acutaas Chemicals, earlier known as Ami Organics, is a Surat-based speciality chemicals company that makes advanced pharmaceutical intermediates, battery electrolyte additives and active ingredients for global customers.

The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2.

Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%.

Roadmap: The company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.

What to watch: Follow capacity additions, new product approvals and export orders.

Lupin vs Alembic Pharmaceuticals vs Acutaas Chemicals on Key Financials

The table below sets the three global generic, formulation and chemistry stocks side by side on revenue, profit and margin, using reported figures.

Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Acutaas Chemicals shows the fastest revenue growth with a 27.5% compound annual rate. A useful habit with global generic, formulation and chemistry stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Global Generic, Formulation and Chemistry Stocks

Every theme carries risks that deserve a check before any decision. For these global generic, formulation and chemistry stocks, the main points are: Long-term pharma export shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Currency moves. Export earnings move with the rupee.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter global generic, formulation and chemistry stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Global Generic, Formulation and Chemistry Stocks

Global generic, formulation and chemistry stocks reward patient research into demand, execution and financial strength. Lupin, Alembic Pharmaceuticals and Acutaas Chemicals each have a clear plan to grow. Based on the 30 October 2026 close, Lupin trades at Rs 2,011, Alembic Pharmaceuticals at Rs 797.85 and Acutaas Chemicals at Rs 4,003.6. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these global generic, formulation and chemistry stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track global generic, formulation and chemistry stocks, set price alerts and get research-backed stock ideas.

What are global generic, formulation and chemistry stocks?

Ans. Global generic, formulation and chemistry stocks are listed companies that sell branded generics and specialty medicines in India and overseas, supply generic formulations to the United States and other markets, and make advanced intermediates for pharma and battery uses. Their earnings depend on approvals, export orders and product mix. This list looks at three of them, Lupin, Alembic Pharmaceuticals and Acutaas Chemicals, using reported FY22 to FY26 financials and the 30 October 2026 closing prices.

Which global generic, formulation and chemistry stocks are covered in this list?

Ans. This list covers Lupin, Alembic Pharmaceuticals and Acutaas Chemicals. Based on the 30 October 2026 close, Lupin traded at Rs 2,011, Alembic Pharmaceuticals at Rs 797.85 and Acutaas Chemicals at Rs 4,003.6. Their return on equity ranges from 11.9% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 27.5%.

Why do global generic, formulation and chemistry stocks have a strong future roadmap in India?

Ans. Global generic, formulation and chemistry stocks have a strong roadmap in India because steady demand for generics, new product approvals and wider use of advanced chemistry keep widening the market for these pharma and chemical companies. The main drivers are as follows. Generic demand. Regulated markets buy more generics. Approvals. New launches add to the product basket. Advanced chemistry. Intermediates serve pharma and batteries. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

How has Alembic Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

How has Acutaas Chemicals performed financially?

Ans. Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%. The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2. Looking ahead, the company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.

What risks should investors check before buying global generic, formulation and chemistry stocks?

Ans. Investors should check a few risks before buying global generic, formulation and chemistry stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of global generic, formulation and chemistry stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 30 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.